phase-iv-995x60.png phase-iv-995x60.png

FEATURED ARTICLES

  • How Pfizer Uses Patient Video To Improve Sickle Cell Trials
    How Pfizer Uses Patient Video To Improve Sickle Cell Trials

    Sickle cell disease is a red blood cell disorder where patients have abnormal hemoglobin in those cells. In this interview Brenda Cooperstone, VP and chief development officer for the specialty care business unit at Pfizer, discusses the efforts made to understand sickle cell patients, their condition, and how the company should interact with them during visits to the emergency room.

  • With RE-VECTO, BI Investigates Clinical Use Of PRAXBIND
    With RE-VECTO, BI Investigates Clinical Use Of PRAXBIND

    Boehringer Ingelheim Pharmaceuticals has announced the launch of a global program designed to evaluate the use of its PRAXBIND medicine, which received FDA approval in October 2015. The program, titled RE-VECTO, will gather data to better understand the actual usage of PRAXBIND in clinical settings.

  • Seamlessly Navigate Clinical Trial Financial Lifecycles
    Seamlessly Navigate Clinical Trial Financial Lifecycles

    At Bioclinica, we are proud to provide our clients with scalable financial lifecycle solutions that can handle global payments as well as integrate with any EDC, CTMS and RTSM. As of April 4, 2016, we've helped Sponsors and CROs make $285 million in payments to 9,012 sites with 70,972 subjects in 63 counties. However, although our technology is a huge factor in our clients' successes, we wouldn't be nearly as successful without the extensive clinical trial expertise that our team members bring to the table. Our team has experience in many facets of clinical trial management, whether from a CRO, Sponsor or technology perspective. They've been able to leverage that experience in order to help our clients navigate the most challenging aspects of the clinical trial financial lifecycle so they can seamlessly automate financial management and improve site satisfaction.

More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Maximize The ROI Of Your Post-Approval Research
    Maximize The ROI Of Your Post-Approval Research

    If your business is like many other pharmaceutical, biotech or medical device companies, your investments in post-approval research are steadily increasing. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!

  • Maximize The ROI Of Your Post-Approval Research Studies
    Maximize The ROI Of Your Post-Approval Research Studies

    Post-approval research studies are becoming increasingly large and complex in the clinical research landscape. These programs are often massive in scope, engaging thousands of physicians and tens of thousands of patients. Unfortunately, post-approval operational strategies have not kept pace with the needs and demands of post-approval (Phase IV) research.

  • Late Stage Clinical Research Services Brochure

    As a result of our holistic approach to Late Stage clinical programs and with our expertise in Product Life Cycle Management, inVentiv Health is strategically positioned to collect real world, differentiating product evidence that can prepare our clients to more successfully go to market.

More White Papers & Case Studies

SERVICES AND PRODUCTS

How Pfizer Uses Patient Video To Improve Sickle Cell Trials How Pfizer Uses Patient Video To Improve Sickle Cell Trials

Sickle cell disease is a red blood cell disorder where patients have abnormal hemoglobin in those cells. In this interview Brenda Cooperstone, VP and chief development officer for the specialty care business unit at Pfizer, discusses the efforts made to understand sickle cell patients, their condition, and how the company should interact with them during visits to the emergency room.

With RE-VECTO, BI Investigates Clinical Use Of PRAXBIND With RE-VECTO, BI Investigates Clinical Use Of PRAXBIND

Boehringer Ingelheim Pharmaceuticals has announced the launch of a global program designed to evaluate the use of its PRAXBIND medicine, which received FDA approval in October 2015. The program, titled RE-VECTO, will gather data to better understand the actual usage of PRAXBIND in clinical settings.

Seamlessly Navigate Clinical Trial Financial Lifecycles Seamlessly Navigate Clinical Trial Financial Lifecycles

At Bioclinica, we are proud to provide our clients with scalable financial lifecycle solutions that can handle global payments as well as integrate with any EDC, CTMS and RTSM. As of April 4, 2016, we've helped Sponsors and CROs make $285 million in payments to 9,012 sites with 70,972 subjects in 63 counties. However, although our technology is a huge factor in our clients' successes, we wouldn't be nearly as successful without the extensive clinical trial expertise that our team members bring to the table. Our team has experience in many facets of clinical trial management, whether from a CRO, Sponsor or technology perspective. They've been able to leverage that experience in order to help our clients navigate the most challenging aspects of the clinical trial financial lifecycle so they can seamlessly automate financial management and improve site satisfaction.

Market Access Insight Commercial Considerations For Pharmaceutical Products Market Access Insight Commercial Considerations For Pharmaceutical Products

Understanding the clinical and technical factors surrounding a product during development is critical for downstream success. John D. McDermott, Jr., Vice President, Covance Market Access Services, discuses approaches to maximize a product’s commercial value.

Clinical Leader Expands Editorial Advisory Board Clinical Leader Expands Editorial Advisory Board

Clinical Leader relies on the feedback of pharma industry professionals and consultants to guide its focus and direction. The website’s editorial advisory board, composed of consultants and executives from the pharma and bio industries, help guide the direction and focus of the site’s editorial content. Clinical Leader has announced that in 2015 it added 17 distinguished individuals to that board, including representatives of Eli Lilly and Company, Pfizer, The Avoca Group, PatientsLikeMe, BMS, Novartis, Shire, and more.

Is The Sunshine Act Reducing Clinical Research Spending? Is The Sunshine Act Reducing Clinical Research Spending?

The intentions behind the passing of the Physicians Payment Sunshine Act were good. The Act required manufacturers of covered drugs, devices, biological products, and medical supplies to annually report to the Centers for Medicare & Medicaid Services (CMS) information regarding payments, ownership, investment interests, and other transfers of value to physicians and teaching hospitals. The intent was to reveal any conflicts of interest that might exist, with the end goal of hopefully bringing down healthcare costs. But even the most well-intentioned acts can have unforeseeable negative results. And it now seems the well-intentioned Sunshine Act may be having the unintended consequence of cutting down on the amount of investment making its way into clinical trials.

More Services & Products